| Literature DB >> 34948033 |
Aleksandra Szczepkowska1, Maciej Wójcik2, Dorota Tomaszewska-Zaremba2, Hanna Antushevich2, Agata Krawczyńska2, Wiktoria Wiechetek2,3, Janina Skipor1, Andrzej Przemysław Herman2.
Abstract
This study was designed to determine the effect of acute caffeine (CAF) administration, which exerts a broad spectrum of anti-inflammatory activity, on the synthesis of pro-inflammatory cytokines and their receptors in the hypothalamus and choroid plexus (ChP) during acute inflammation caused by the injection of bacterial endotoxin-lipopolysaccharide (LPS). The experiment was performed on 24 female sheep randomly divided into four groups: control; LPS treated (iv.; 400 ng/kg of body mass (bm.)); CAF treated (iv.; 30 mg/kg of bm.); and LPS and CAF treated. The animals were euthanized 3 h after the treatment. It was found that acute administration of CAF suppressed the synthesis of interleukin (IL-1β) and tumor necrosis factor (TNF)α, but did not influence IL-6, in the hypothalamus during LPS-induced inflammation. The injection of CAF reduced the LPS-induced expression of TNF mRNA in the ChP. CAF lowered the gene expression of IL-6 cytokine family signal transducer (IL6ST) and TNF receptor superfamily member 1A (TNFRSF1) in the hypothalamus and IL-1 type II receptor (IL1R2) in the ChP. Our study on the sheep model suggests that CAF may attenuate the inflammatory response at the hypothalamic level and partly influence the inflammatory signal generated by the ChP cells. This suggests the potential of CAF to suppress neuroinflammatory processes induced by peripheral immune/inflammatory challenges.Entities:
Keywords: IL-1β; IL-6; IL1R1; IL1R2; IL6R; IL6ST; LPS; TNFRSF1A; TNFRSF1B; TNFα; brain
Mesh:
Substances:
Year: 2021 PMID: 34948033 PMCID: PMC8706723 DOI: 10.3390/ijms222413237
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Mean (±SEM) concentration and gene expression (insert) of pro-inflammatory cytokines: interleukin 1beta (A), interleukin 6 (B) and tumor necrosis factor-alpha (C) in the ovine hypothalamus in saline- (C/C, 0.9% NaCl iv., white bars), lipopolysaccharide- (LPS/C, 400 ng/kg of body mass (bm.), iv., red bars), caffeine- (C/CAF, 30 mg/kg of bm., iv., grey bars) and LPS/CAF- (red-grey hatched bars) treated female sheep. Different letters indicate significant differences at p < 0.05, according to one-way ANOVA followed by Fisher’s post hoc test comparing groups with each other.
The effect of caffeine on the relative gene expression (mean ± SEM; n = 6) of pro-inflammatory cytokines receptors in the ovine hypothalamus in basal and lipopolysaccharide-challenge conditions.
| Gene | C/C | LPS/C | C/CAF | LPS/CAF |
|---|---|---|---|---|
| 1 ± 0.1 A | 2.8 ± 0.4 B | 1.3 ± 0.1 A | 2.3 ± 0.3 B | |
| 1 ± 0.1 A | 4.5 ± 0.7 B | 1.5 ± 0.1 A | 4.2 ± 0.6 B | |
| 1 ± 0.1 A | 1 ± 0.1 A | 1.1 ± 0.1 A | 1 ± 0.1 A | |
| 1 ± 0.1 A | 1.4 ± 0.1 C | 1.2 ± 0.1 B | 1.3 ± 0.1 B | |
| 1 ± 0.1 A | 1.6 ± 0.2 B | 0.8 ± 0.1 A | 1 ± 0.1 A | |
| 1 ± 0.1 A | 1.9 ± 0.3 B | 1.1 ± 0.1 A | 1.8 ± 0.1 B |
C/C—double treated with saline (0.9% NaCl iv.), LPS/C—treated with lipopolysaccharide (LPS, 400 ng/kg of bm., iv.) followed by saline, C/CAF –treated with saline followed by caffeine (CAF, 30 mg/kg of body mass (bm.), iv.), LPS/CAF—treated with LPS followed by CAF. Gene expression data were normalized to the average relative level of this mRNA expression in the control sheep (C/C), which was set to 1.0. Different letters indicate significant differences at p < 0.05, according to one-way ANOVA followed by Fisher’s post hoc test comparing groups with each other.
The effect of caffeine on the relative gene expression (mean ± SEM; n = 6) of pro-inflammatory cytokines and their receptors in the ovine choroid plexus in basal and lipopolysaccharide-challenge conditions.
| Gene | C/C | LPS/C | C/CAF | LPS/CAF |
|---|---|---|---|---|
| 1 ± 0.1 A | 7.8 ± 2.1 B | 0.7 ± 0.1 A | 9.8 ± 3.1 B | |
| 1 ± 0.1 A | 3.6 ± 0.8 B | 2.3 ± 0.3 A | 4.1 ± 0.4 B | |
| 1 ± 0.2 A | 9.7 ± 1.6 C | 2.1 ± 0.3 A | 6.5 ± 0.3 B | |
| 1 ± 0.1 A | 587.4 ± 146.0 C | 1.9 ± 0.2 B | 489.7 ± 58.0 C | |
| 1 ± 0.1 AB | 0.8 ± 0.2 A | 1.4 ± 0.2 B | 0.8 ± 0.1 A | |
| 1 ± 0.1 A | 2.8 ± 0.4 C | 1.9 ± 0.2 B | 2.9 ± 0.2 C | |
| 1 ± 0.1 AB | 2.1 ± 0.8 B | 0.7 ± 0.1 A | 0.8 ± 0.2 A | |
| 1 ± 0.1 A | 1.5 ± 0.2 B | 1.1 ± 0.1 A | 1.4 ± 0.1 B | |
| 1 ± 0.1 A | 3.8 ± 0.8 B | 1.7 ± 0.3 A | 4.0 ± 0.3 B |
C/C—double treated with saline (0.9% NaCl iv.), LPS/C—treated with lipopolysaccharide (LPS, 400 ng/kg of bm., iv.) followed by saline, C/CAF –treated with saline followed by caffeine (CAF, 30 mg/kg of body mass (bm.), iv.), LPS/CAF—treated with LPS followed by CAF. Gene expression data were normalized to the average relative level of this mRNA expression in the control sheep (C/C), which was set to 1.0. Different letters indicate significant differences at p < 0.05, according to one-way ANOVA followed by Fisher’s post hoc test comparing groups with each other.
Experiment organization chart.
| Group | No. of | Experimental | Dose [ng/kg] | Experimental | Dose [mg/kg] |
|---|---|---|---|---|---|
|
| 6 | NaCl | 0 | NaCl | 0 |
|
| 6 | LPS | 400 | NaCl | 0 |
|
| 6 | NaCl | 0 | caffeine | 30 |
|
| 6 | LPS | 400 | caffeine | 30 |
C/C—saline-treated, control; LPS/C—lipopolysaccharide-treated; C/CAF—caffeine-treated; LPS/CAF—lipopolysaccharide- and caffeine-treated.
Sequences of oligonucleotide primers used for real-time PCR in the hypothalamus and choroid plexus.
| Gene | (Forward/Reverse) Sequence 5′ → 3′ | Amplicon | References/ | |
|---|---|---|---|---|
|
|
| F: CAGCCGTGCAGTCAGTAAAA R: GAAGCTCATGCAGAACACCA | 137 | [ |
|
| F: GGGAAGGGTCCACCTGTAAC R: ACAATGCTTTCCCCAACGTA | 124 | [ | |
|
| F: CGCCAGGCATACTCAGAAA R: GAGAACGTGGCAGCTTCTTT | 162 | [ | |
|
| F: GTTCAATCAGGCGATTTGCT R: CCTGCGATCTTTTCCTTCAG | 165 | [ | |
|
| F: TCAGCGACTCCGGAAACTAT R: CCGAGGACTCCACTCACAAT | 149 | [ | |
|
| F: GGCTTGCCTCCTGAAAAACC R: ACTTCTCTGTTGCCCACTCAG | 139 | [ | |
|
| F: CAAATAACAAGCCGGTAGCC R: AGATGAGGTAAAGCCCGTCA | 153 | [ | |
|
| F: AGGTGCCGGGATGAAATGTT R: CAGAGGCTGCAGTTCAGACA | 137 | [ | |
|
| F: ACCTTCTTCCTCCTCCCAAA R: AGAAGCAGACCCAATGCTGT | 122 | [ | |
|
|
| F: AGAAGGCTGGGGCTCACT R: GGCATTGCTGACAATCTTGA | 134 | [ |
|
| F: TGACCCCTTCATTGACCTTC R: GATCTCGCTCCTGGAAGATG | 143 | [ | |
|
| F: CTTCCTTCCTGGGCATGG R: GGGCAGTGATCTCTTTCTGC | 168 | [ | |
|
| F: GCCAACCGTGAGAAGATGAC R: TCCATCACGATGCCAGTG | 122 | [ | |
|
| F: CTGGGGACCTACGGGATATT R: GACATGACCGGCTTGAAAAT | 115 | [ |
IL1B—interleukin 1-beta; IL1R1—interleukin 1 receptor, type I; IL1R2—interleukin 1 receptor, type II; IL6—interleukin 6; IL6R—interleukin 6 receptor; IL6ST—glycoprotein 130; TNF—tumor necrosis factor; TNFRSF1A—tumor necrosis factor receptor superfamily member 1A; TNFRSF1B—tumor necrosis factor receptor superfamily member 1B; GAPDH—glyceraldehyde-3-phosphate dehydrogenase; ACTB—beta-actin; HDAC1—histone deacetylase 1; ChP—choroid plexus.